Literature DB >> 6439818

Initiation of antibiotic production by the stringent response of Bacillus subtilis Marburg.

K Ochi, S Ohsawa.   

Abstract

Bacillus subtilis Marburg was found to produce an appreciable amount of an antibiotic in a synthetic medium. Antibiotic activity was produced in parallel with cell growth, and production stopped at the end of exponential growth. When the synthetic medium was supplemented with a small amount of Casamino acids, however, antibiotic was made only at the end of growth and in lesser amounts. The ability of cells to produce the antibiotic increased when stringent (rel+ = wild-type) cells underwent a partial stringent response. These conditions also initiated extensive sporulation. An isogenic relaxed (rel) strain produced little antibiotic activity, which decreased under partial amino acid deprivation. In rel+ cells, the addition of a low concentration of chloramphenicol, which reduces ppGpp synthesis, also reduced antibiotic synthesis in both normal and amino acid-starved bacteria, without appreciably affecting their growth rate. Guanosine starvation of a gua mutant initiated sporulation, but decreased antibiotic production. The results show that the stringent response initiates both sporulation (differentiation) and antibiotic production (secondary metabolism), but by different mechanisms. It appears that sporulation results from a decrease of GTP, whereas antibiotic synthesis results from a different effect of the stringent response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439818     DOI: 10.1099/00221287-130-10-2473

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  13 in total

1.  RelA protein is involved in induction of genetic competence in certain Bacillus subtilis strains by moderating the level of intracellular GTP.

Authors:  Takashi Inaoka; Kozo Ochi
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

Review 2.  Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response.

Authors:  P Gilbert; P J Collier; M R Brown
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  ADP-ribosylation of proteins in Bacillus subtilis and its possible importance in sporulation.

Authors:  J W Huh; J Shima; K Ochi
Journal:  J Bacteriol       Date:  1996-08       Impact factor: 3.490

4.  The mthA mutation conferring low-level resistance to streptomycin enhances antibiotic production in Bacillus subtilis by increasing the S-adenosylmethionine pool size.

Authors:  Shigeo Tojo; Ji-Yun Kim; Yukinori Tanaka; Takashi Inaoka; Yoshikazu Hiraga; Kozo Ochi
Journal:  J Bacteriol       Date:  2014-02-07       Impact factor: 3.490

5.  Identification and characterization of genes controlled by the sporulation-regulatory gene spo0H in Bacillus subtilis.

Authors:  K J Jaacks; J Healy; R Losick; A D Grossman
Journal:  J Bacteriol       Date:  1989-08       Impact factor: 3.490

6.  Induction of penicillin-binding proteins under catabolite-repressed conditions.

Authors:  C E Buchanan
Journal:  J Bacteriol       Date:  1985-06       Impact factor: 3.490

7.  Glucose uptake pathway-specific regulation of synthesis of neotrehalosadiamine, a novel autoinducer produced in Bacillus subtilis.

Authors:  Takashi Inaoka; Kozo Ochi
Journal:  J Bacteriol       Date:  2006-10-20       Impact factor: 3.490

8.  Metabolic initiation of differentiation and secondary metabolism by Streptomyces griseus: significance of the stringent response (ppGpp) and GTP content in relation to A factor.

Authors:  K Ochi
Journal:  J Bacteriol       Date:  1987-08       Impact factor: 3.490

9.  Acquisition of certain streptomycin-resistant (str) mutations enhances antibiotic production in bacteria.

Authors:  Y Hosoya; S Okamoto; H Muramatsu; K Ochi
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Extracellular control of spore formation in Bacillus subtilis.

Authors:  A D Grossman; R Losick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.